Skip to main content
. 2021 Mar 23;60(8):1015–1027. doi: 10.1007/s40262-021-00990-7

Fig. 4.

Fig. 4

Somapacitan AUC0–168 h (ng·h/mL) after the last dose on day 15 for a four kidney impairment groups and the normal function group, and b mild and moderate hepatic impairment groups and the normal hepatic function group. Filled symbols represents the mean, center line represents the median, box represents the 25th and 75th percentiles, and whiskers represent the range. AUC0–168 h area under the plasma drug concentration-time curve, n number of subjects